Filter by: patients
Home > Community Treatment Reports and Side Effects > AVP-923 (DM/Q) Treatment Report
What is AVP-923 (DM/Q)?

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis and Multiple Sclerosis

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Emotional lability 3 1 Efficacy_major
Other 1 0

See all 3 patients currently taking AVP-923 (DM/Q)

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 1
None
 0

Commonly reported side effects, conditions, and hospitalizations associated with AVP-923 (DM/Q)

Headaches 1

Reported Dosages

  30 mg daily 60 mg daily 80 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking AVP-923 (DM/Q) (multiple reasons could be selected)
Reason # Patients Percentage of patients
Side effects too severe 1   Side effects too severe: 100%

See all 1 patient who’ve stopped taking AVP-923 (DM/Q)

Reported Duration See details about how long patients take this treatment ▼

Stopped Taking AVP-923 (DM/Q)

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of AVP-923 (DM/Q)

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of AVP-923 (DM/Q)

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 1 100%

Cost

Paid out of pocket

Cost of AVP-923 (DM/Q)

$200+
 0 0%
$100-199
 0 0%
$50-99
 1 100%
$25-49
 0 0%
< $25
 0 0%

Report created on May 28, 2012.